IPS

CNBC | January 16, 2017

Turbulence and turmoil in the pharmaceutical industry will only prove to be temporary in spite of President-elect Donald Trump's vow to clamp down on drug pricing, according to Royal Philips' chief executive. Frans Van Houten, chief executive of the medical equipment and technology firm, described the current situation in the pharmaceutical industry as "uncertain" however he remained confident the negative sentiment surrounding healthcare stocks would be reversed in time....

pharmaphorum.com | February 21, 2017

NICE has issued draft guidance which rejects Ipsen’s Cabometyx for NHS use in previously treated advanced renal cell carcinoma (RCC). Cabometyx (cabozantinib), is an important new treatment for the company, and its pivotal trials showed the drug can extend overall survival in previously treated patients, the first such drug to show these benefits....

PR Newswire | January 11, 2018

The U.S. Food and Drug Administration has approved an antipsychotic, aripiprazole, as the first drug to contain a "digital ingestion tracking system" that can tell whether the drug has been taken a technology that even a leading U.S. psychiatrist likened to "a biomedical Big Brother." The Citizens Commission on Human Rights (CCHR), an international mental health industry watchdog, says Congress should investigate how the FDA could approve such technology to be used on the ver...

World Pharma News | January 30, 2018

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel formation and drugs targeting this event. The technology recreates a human blood vessel and shows how new capillaries grow from a single vessel (parent vessel) in response to proper biochemical signaling cues. The technology can further be used to develop drugs targeting this growth as a therapeutic approach to treat cancer and ...